These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 30359962)

  • 1. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Bifari F; Manfrini R; Dei Cas M; Berra C; Siano M; Zuin M; Paroni R; Folli F
    Pharmacol Res; 2018 Nov; 137():219-229. PubMed ID: 30359962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective.
    Yadav P; Khurana A; Bhatti JS; Weiskirchen R; Navik U
    Pharmacol Res; 2022 Oct; 184():106426. PubMed ID: 36075510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.
    Liu Y; Wei R; Hong TP
    World J Gastroenterol; 2014 Jul; 20(27):9090-7. PubMed ID: 25083081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.
    Junker AE; Gluud LL; van Hall G; Holst JJ; Knop FK; Vilsbøll T
    J Hepatol; 2016 Apr; 64(4):908-15. PubMed ID: 26626496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides.
    Kořínková L; Pražienková V; Černá L; Karnošová A; Železná B; Kuneš J; Maletínská L
    Front Endocrinol (Lausanne); 2020; 11():597583. PubMed ID: 33324348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease.
    Alvares D; Hoffman S; Stankovic B; Adeli K
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Mar; 1864(3):326-334. PubMed ID: 30578967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M; Imprialos K; Stavropoulos K; Athyros VG
    Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.
    Dhir G; Cusi K
    J Investig Med; 2018 Jan; 66(1):7-10. PubMed ID: 28918389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?
    Vincent RK; Williams DM; Evans M
    Diabetes Obes Metab; 2020 Dec; 22(12):2227-2240. PubMed ID: 32945071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.
    Chen Y; Xu YN; Ye CY; Feng WB; Zhou QT; Yang DH; Wang MW
    Acta Pharmacol Sin; 2022 May; 43(5):1156-1166. PubMed ID: 34934197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.
    Li CL; Zhao LJ; Zhou XL; Wu HX; Zhao JJ
    J Huazhong Univ Sci Technolog Med Sci; 2015 Jun; 35(3):333-336. PubMed ID: 26072069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD.
    Jiang H; Zang L
    Curr Pharm Des; 2024; 30(2):100-114. PubMed ID: 38532322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis.
    Ye X; Chen Y; Qi J; Zhu S; Wu Y; Xiong J; Hu F; Guo Z; Liang X
    Eur J Pharmacol; 2023 Aug; 952():175811. PubMed ID: 37245859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update.
    Sofogianni A; Filippidis A; Chrysavgis L; Tziomalos K; Cholongitas E
    World J Hepatol; 2020 Aug; 12(8):493-505. PubMed ID: 32952876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.